Abstract: Disclosed is a system and method to maintain the health of a control system. A recording of running status of process control system software is performed. Then a health assessment of a process control system is carried out using the recorded running status. Using this information, at least one health maintenance recommendation is generated. The recommendations are then implemented to maintain the health of a process control system.

Abstract: In one embodiment, a system includes system includes a data collection system configured to collect a data from a control system. The system further includes a configuration management system configured to manage a hardware configuration and a software configuration for the control system based on the data. The system additionally includes a rule engine configured to use the data as input and to output a health assessment by using a rule database configured to store at least one rule, and a report generator configured to provide a health assessment for the control system. The system also includes a rule editor configured to create the at least one rule, update the at least one rule, delete the at least one rule, or a combination thereof.

Abstract: Disclosed is a system and method to maintain the health of a control system. A recording of running status of process control system software is performed. Then a health assessment of a process control system is carried out using the recorded running status. Using this information, at least one health maintenance recommendation is generated. The recommendations are then implemented to maintain the health of a process control system.

Abstract: In one embodiment, a system includes a data collection system configured to collect a data from a control system by using an offline mode of operations. The system further includes a configuration management system configured to manage a hardware configuration and a software configuration for the control system based on the data. The system additionally includes a rule engine configured to use the data as input and to output a health assessment by using a rule database, and a report generator configured to provide a health assessment for the control system.

Abstract: In one embodiment, a system includes system includes a data collection system configured to collect a data from a control system. The system further includes a configuration management system configured to manage a hardware configuration and a software configuration for the control system based on the data. The system additionally includes a rule engine configured to use the data as input and to output a health assessment by using a rule database configured to store at least one rule, and a report generator configured to provide a health assessment for the control system. The system also includes a rule editor configured to create the at least one rule, update the at least one rule, delete the at least one rule, or a combination thereof.

Abstract: In one embodiment, a system includes system includes a data collection system configured to collect a data from a control system. The system further includes a configuration management system configured to manage a hardware configuration and a software configuration for the control system based on the data. The system additionally includes a rule engine configured to use the data as input and to output a health assessment by using a rule database configured to store at least one rule, and a report generator configured to provide a health assessment for the control system. The system also includes a rule editor configured to create the at least one rule, update the at least one rule, delete the at least one rule, or a combination thereof.

Abstract: A system includes a human machine interface (HMI) health advisor system including a health advisor suite having a processor. The processor of the health advisor suite is configured to receive operational data regarding a HMI device, wherein the operational data includes configuration data, log data, or a combination thereof. The processor is also configured to apply a plurality of rules to the operational data to proactively determine a HMI issue. The processor is also configured to identify a solution to the HMI issue from a plurality of known solutions to HMI issues. The processor is further configured to generate a configuration report for the HMI device based on the configuration data and to generate a health assessment report for the HMI device. Additionally, the health assessment report comprises the HMI issue and the solution to the HMI issue.

Abstract: In one embodiment, a system includes a data collection system configured to collect a data from a control system by using an offline mode of operations. The system further includes a configuration management system configured to manage a hardware configuration and a software configuration for the control system based on the data. The system additionally includes a rule engine configured to use the data as input and to output a health assessment by using a rule database, and a report generator configured to provide a health assessment for the control system.

Abstract: A method of treating CD33+ acute and chronic myeloid leukemia in animals including humans, using fraction nos. 1 and 9 obtained from water:methanol fraction by column chromatography, with ratio of water and methanol ranging between 1:5 to 5:1, wherein said water:methanol fraction is obtained from the polar extract of Piper betel by HPLC, with retention time of 3.6 and 24.0 minutes respectively, with said fractions used both individually, and in combination.

Abstract: A method of treating CD33+ acute and chronic myeloid leukemia in animals including humans, using fraction nos. 1 and 9 obtained from water:methanol fraction by column chromatography, with ratio of water and methanol ranging between 1:5 to 5:1, wherein said water:methanol fraction is obtained from the polar extract of Piper betel by HPLC, with retention time of 3.6 and 24.0 minutes respectively, with said fractions used both individually, and in combination.

Abstract: A method of treating CD33+ acute and chronic myeloid leukemia in animals including humans, using fraction nos. 1 and 9 obtained from water:methanol fraction by column chromatography, with ratio of water and methanol ranging between 1:5 to 5:1, wherein said water:methanol fraction is obtained from the polar extract of Piper betel by HPLC, with retention time of 3.6 and 24.0 minutes respectively, with said fractions used both individually, and in combination.

Abstract: A method of treating CD33+ acute and chronic myeloid leukemia in animals including humans, using fraction nos. 1 and 9 obtained from water: methanol fraction by column chromatography, with ratio of water and methanol ranging between 1:5 to 5:1, wherein said water:methanol fraction is obtained from the polar extract of Piper betel by HPLC, with retention time of 3.6 and 24.0 minutes respectively, with said fractions used both individually, and in combination, and a composition comprising the said fraction nos. 1 and 9.

Abstract: A method of treating CD33+ acute and chronic myeloid leukemia in animals including humans, using fraction nos. 1 and 9 obtained from water:methanol fraction by column chromatography, with ratio of water and methanol ranging between 1:5 to 5:1, wherein said water:methanol fraction is obtained from the polar extract of Piper betel by HPLC, with retention time of 3.6 and 24.0 minutes respectively, with said fractions used both individually, and in combination.

Abstract: A new herbal-based composition and method for treatment of CD33+ acute and chronic myeloid leukemia by Piper betel leaf extracts, and to provide a process for the isolation of active fractions from leaves or any other plant parts of Piper betel to treat CD33+ AML and CML with a simplified method of isolation of active components from all plant parts of Piper betel possessing biological activities relevant to the treatment of CD33+ AML and CML.

Abstract: The present invention relates to a method of treating CD33+ acute and chronic myeloid leukemia in animals including humans, using fraction nos. 1 and 9 obtained from water:methanol fraction by column chromatography, with ratio of water and methanol ranging between 1:5 to 5:1, wherein said water:methanol fraction is obtained from the polar extract of piper betel by HPLC, with retention time of 3.6 and 24.0 minutes respectively, with said fractions used both individually, and in combination, and a composition comprising the said fraction nos. 1 and 9.

Abstract: A method of treating CD33+ acute and chronic myeloid leukemia in animals including humans, using fraction nos. 1 and 9 obtained from water:methanol fraction by column chromatography, with ratio of water and methanol ranging between 1:5 to 5:1, wherein said water:methanol fraction is obtained from the polar extract of Piper betel by HPLC, with retention time of 3.6 and 24.0 minutes respectively, with the fractions used both individually, and in combination, and a composition including the fraction nos. 1 and 9.

Abstract: The present invention relates to a method of treating CD33+ acute and chronic myeloid leukemia in animals including humans, using fraction nos. 1 and 9 obtained from water:methanol fraction by column chromatography, with ratio of water and methanol ranging between 1:5 to 5:1, wherein said water:methanol fraction is obtained from the polar extract of piper betel by HPLC, with retention time of 3.6 and 24.0 minutes respectively, with said fractions used both individually, and in combination, and a composition comprising the said fraction nos. 1 and 9.

Abstract: This invention relates to synthetic garnite tiles made essentially from garnite sand and a process for the production of synthetic garnite tiles essentially from garnet sand which is a by-product of beach sand from rare earths extraction, said process comprising mixing beach sand garnet, feldspar and clay thoroughly; pressing the mixture using a press at a pressure in the range of 40-80 MPa to form tiles of desired shapes and sizes; drying the tiles so formed at a temperature of 100-120.degree. C.; firing the dried tiles at a temperature in the range of 1050-1250.degree. C. with a soaking for a period ranging from 1.5 to 2.5 hours, and polishing the resultant tiles.

Abstract: This invention relates to synthetic granite tiles made essentially from garnite sand and a process for the production of synthetic garnite tiles essentially from garnet sand which is a by-product of beach sand from rare earths extraction, said process comprising mixing beach sand garnet, feldspar and clay thoroughly; pressing the mixture using a press at a pressure in the range of 40-80 MPa to form tiles of desired shapes and sizes; drying the tiles so formed at a temperature of 100.degree.-120.degree. C.; firing the dried tiles at a temperature in the range of 1050.degree.-1250.degree. C. with a soaking for a period ranging from 1.5 to 2.5 hours, and polishing the resultant tiles.